Osaka, Japan

Kousuke Tani

This inventor holds 33 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Ono Pharmaceutical Co., Ltd., Ono Pharmaceuticals Co., Ltd., Ono Pharmaceuticalco.,ltd.. Active years: 2000-2025.

USPTO Granted Patents = 33 

% Patents Active = 60.6

 

 

Average Co-Inventor Count = 4.4

ph-index = 10

Forward Citations = 284(Granted Patents)


Location History:

  • Mishima-gun, JP (2001 - 2011)
  • Osaka, JP (2000 - 2023)

Company Filing History:


Years Active: 2000-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Tricyclic Compound
Bicyclic Compound
EP4 Antagonist
EP2 Agonist
ALXR Agonist
Carboxylic Acid Derivatives
Medicinal Composition
Prostaglandin Derivatives
Spiro Compound
Pharmaceutical Agent
Active Ingredient
Drug Composition
33 patents (USPTO):Explore Patents

Title: The Innovative Journey of Kousuke Tani

Introduction: Kousuke Tani, a pioneering inventor hailing from Osaka, Japan, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Tani's latest patents focus on advancements in artificial intelligence and robotics, showcasing his commitment to pushing the boundaries of technological possibilities.

Career Highlights: With a career spanning over two decades, Tani has established himself as a leading figure in the tech industry, known for his out-of-the-box thinking and inventive solutions to complex problems.

Collaborations: Throughout his career, Tani has collaborated with top research institutions and leading tech companies to bring his ideas to life, fostering a culture of innovation and creativity in the industry.

Conclusion: Kousuke Tani's relentless pursuit of innovation and his passion for creating cutting-edge technologies continue to inspire the next generation of inventors and shape the future of the tech landscape.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…